Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2018-03-09 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
2017年度独立董事（姚明龙）述职报告
Board/Management Information Classification · 95% confidence The document is a detailed 2017 annual report by an independent director of 普洛药业股份有限公司, describing the director's duties, attendance at meetings, opinions on various company reports and proposals, and efforts to protect shareholder rights. It references specific reports such as the 2016 annual report, 2017 half-year report, and 2017 third-quarter report, but the document itself is a director's duty report rather than a full financial report or audit. It is not a short announcement or certification but a substantive narrative on board activities and governance. This fits best under Board/Management Information (MANG), which covers announcements of changes or reports related to board or senior management activities. The document is not an Annual Report (10-K) or Audit Report (AR) because it does not contain full financial statements or audit results, nor is it a Regulatory Filing (RNS) or Report Publication Announcement (RPA) since it is a substantive report by a board member. Therefore, the classification is MANG with high confidence.
2018-03-09 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by an accounting firm (山东和信会计师事务所) and dated March 9, 2018. The report discusses the audit of the effectiveness of internal control over financial reporting as of December 31, 2017. It includes the auditor's responsibilities, the company's responsibilities, and the auditor's opinion on the effectiveness of internal controls. The document is a standalone audit report focused on internal control over financial reporting, not a full annual report or other type of filing. Therefore, it fits the definition of an Audit Report / Information (AR). The document length is short (1158 characters) but contains substantive audit opinion content, so it is not merely an announcement or certification. Hence, the classification is AR with high confidence. FY 2017
2018-03-09 Chinese
第七届监事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of 普洛药业股份有限公司 regarding the approval of the 2017 Annual Report, Supervisory Board Work Report, Financial Work Report, Profit Distribution Plan, Internal Control Evaluation Report, and other related matters. It includes voting results and references to detailed reports published elsewhere (on 巨潮资讯网). The document itself does not contain the full annual report or detailed financial statements but rather the resolutions and approvals related to these reports. The document length is short (1918 characters) and primarily serves as an announcement of meeting decisions and approvals rather than the full report itself. Therefore, it fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice, not the full Annual Report (10-K) or other detailed reports.
2018-03-09 Chinese
关于授权董事长进行理财投资的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the authorization of the chairman to conduct financial investment using idle funds. It details the investment scope, risk analysis, control measures, and includes opinions from independent directors and the sponsoring institution. The document is relatively short (1626 characters) and does not contain financial statements or substantive financial data. It is an announcement about a corporate decision related to investment authorization rather than a financial report or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2018-03-09 Chinese
关于召开2017年度股东大会的通知
AGM Information Classification · 100% confidence The document is a notice about the convening of the 2017 Annual General Meeting (AGM) of 普洛药业股份有限公司. It details the meeting time, location, agenda items including the review of the 2017 annual report, board and supervisory reports, financial reports, profit distribution plan, and other proposals. It also includes instructions for shareholder registration and voting procedures, including online voting. The document does not contain the actual annual report or financial statements but rather serves as an announcement and invitation to the AGM with relevant procedural details. The document length is 4218 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2018-03-09 Chinese
2017年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an audit report (审计报告) for 普洛药业股份有限公司, covering the financial statements for the year ended December 31, 2017. It includes detailed auditor opinions, key audit matters, responsibilities of management and auditors, and extensive financial statements such as balance sheet, income statement, cash flow statement, and equity changes. The presence of an auditor's opinion, audit basis, and detailed financial data confirms this is a standalone audit report rather than a full annual report or an announcement. The document length (15,000 characters) and content depth further support this classification. Therefore, the document fits the category of Audit Report / Information (AR). FY 2017
2018-03-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.